NCT00325494View on ClinicalTrials.gov

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Pancreatic CancerMesotheliomaOvarian CancerNon-Small Cell Lung Cancer
Interventions
DRUG

MORAb-009

Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

20892-1922

National Cancer Institute, Bethesda

Sponsors

Lead Sponsor

Morphotek
All Listed Sponsors
lead

Morphotek

INDUSTRY